News
DARE
0.2860
-3.80%
-0.0113
12 Health Care Stocks Moving In Wednesday's After-Market Session
Acrivon Therapeutics stock rose 12.3% to $10.67 during Wednesday's after-market session. The company's, Q1 earnings came out today. Amarin Corp stock moved upwards by 8.12% and Universe Pharmaceuticals stock rose 7.47% in the same session.
Benzinga · 15h ago
DARE BIOSCIENCE: TO GET $1 MLN AS LATEST INSTALLMENT UNDER GRANT DEAL TO ADVANCE DEVELOPMENT OF DARÉ'S INVESTIGATIONAL CONTRACEPTIVE DARE-LARC1
Reuters · 1d ago
DARE BIOSCIENCE: UNDER TERMS OF GRANT AGREEMENT, DARÉ MAY GET UP TO ABOUT $49 MLN TO SUPPORT NONCLINICAL DEVELOPMENT OF DARE-LARC1
Reuters · 1d ago
Press Release: Daré Bioscience Announces Grant -2-
Failure or delay in starting, conducting and completing clinical trials of a product candidate; Daré's ability to design and conduct successful clinical trials. The risk that the FDA, other regulatory authorities and investors may not accept or agree with the results of clinical studies. Daré Bioscience's dependence on third parties to conduct clinical trials and commercialize its product candidates.
Dow Jones · 1d ago
Press Release: Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience's DARE-LARC1 Platform Technology has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases. Daré will receive a payment of $1 million to support the development of the company's investigational contraceptive. The company is developing a long-acting, reversible contraceptive with precision dosing, extended device duration and wireless control. The technology could be used to treat diabetes, obesity and other conditions.
Dow Jones · 1d ago
Weekly Report: what happened at DARE last week (0415-0419)?
Weekly Report · 3d ago
Dare Bioscience Cut to Hold From Buy by Brookline Capital
Dow Jones · 04/17 17:38
Brookline Capital Downgrades Dare Bioscience to Hold
Benzinga · 04/17 17:28
12 Health Care Stocks Moving In Wednesday's Intraday Session
INVO Bioscience stock rose 275.0% to $2.85 during Wednesday's regular session. The company's Q4 earnings report came out yesterday. Vanda Pharma stock moved upwards by 33.33% during the session. Losers include Longeveron (NASDAQ:LGVN) and Dare BiosScience.
Benzinga · 04/17 16:31
Weekly Report: what happened at DARE last week (0408-0412)?
Weekly Report · 04/15 10:07
Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive
Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women. Pivotal Phase 3 contraceptive efficacy clinical study of ovaprene currently enrolling has the potential to be first FDA-approved hormone-free monthly intravaginal contraceptive for women.
Benzinga · 04/11 12:15
Weekly Report: what happened at DARE last week (0401-0405)?
Weekly Report · 04/08 10:10
Analysts Are Bullish on These Healthcare Stocks: BiomX (PHGE), Daré Bioscience (DARE)
TipRanks · 04/03 18:50
Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Legend Biotech (LEGN) and Imunon (IMNN)
TipRanks · 04/01 10:20
Weekly Report: what happened at DARE last week (0325-0329)?
Weekly Report · 04/01 10:09
Daré Bioscience’s Reverse Stock Split: Navigating the Risks of Market Perception and Shareholder Liquidity
TipRanks · 03/30 06:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) shares increased by 73.2% to $1.1 during Thursday's after-market session. Dare Bioscience stock rose 12.19% and Sunshine Biopharma stock increased by 37.85%. Vivos Therapeutics stock fell 12.6% as the company's Q4 earnings came out today.
Benzinga · 03/28 20:31
After-Hours Earnings Report for March 28, 2024 : ACHV, ACNT, AREC, AXDX, CPTN, CURV, DARE, DNMR, DYAI, FORA, HSDT, INLX
NASDAQ · 03/28 18:00
DARE Stock Earnings: Dare Bioscience Beats EPS, Beats Revenue for Q4 2023
Dare Bioscience reported earnings per share of -6 cents for the fourth quarter of 2023. The company reported revenue of $1.81 million. This was 1.01% better than the analyst estimate for the same period. Dare Biosscience reported results for the last quarter of 2013.
Investorplace · 03/28 17:53
Dare Bioscience Q4 EPS $(0.06) Beats $(0.10) Estimate, Sales $1.81M Beat $1.79M Estimate
Dare Bioscience reported quarterly losses of $0.06 per share. The company beat the analyst consensus estimate by 40%. The company reported quarterly sales of $1.81 million which beat the estimate by 1.01%. The stock is up 68.42 percent in the last month.
Benzinga · 03/28 15:15
More
Webull provides a variety of real-time DARE stock news. You can receive the latest news about Dare Bioscience Inc through multiple platforms. This information may help you make smarter investment decisions.
About DARE
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.